-The Hindu Business Line Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on Pretomanid A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of Pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent. The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint...

-The Hindu Business Line The drug was developed by the TB Alliance, funded by various governments and philanthropic sources Hyderabad: The slew of newer TB drugs that have hit the market recently promise to tackle the disease better, but the high price can prove a dampener to realise the goal of taming the deadly disease on a war footing, feel experts, advocacy groups and medical organisations who are meeting this week in...